WithdrawnNot Applicable

Biomarker for Hurler Disease (BioHurler)

Stopped: Transition to BioMetabol

Egypt, Germany, India0Started 2018-08-20

Plain-language summary

Development of a new MS-based biomarker for the early and sensitive diagnosis of Hurler disease from plasma. Testing for clinical robustness, specificity and long-term stability of the biomarker.

Who can participate

Age range2 Months

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. \- Positive family anamnesis for Hurler disease
✓. \- Macrocephaly
✓. \- Deformed bones and stiff joints, especially the spine, hips, knees, wrists and fingers
✓. \- Musculoskeletal alterations including short stature
✓. \- Developmental delay and/or progressive mental deterioration

What they're measuring

Development of a new MS-based biomarker for the early and sensitive diagnosis of Hurler disease from blood

Timeframe: 24 months

Trial details

NCT IDNCT02298712

SponsorCENTOGENE GmbH Rostock

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2021-02-28

View on ClinicalTrials.gov More Mucopolysaccharidosis Type I trials